Novo Nordisk, headquartered in Copenhagen, Denmark, is a multinational biopharmaceutical corporation that engages in the research, development, manufacture, and marketing of pharmaceutical products and services worldwide. Created in 1989 by the merger of two longstanding Danish pharmaceutical companies, its main areas are diabetes and obesity treatment. It is one of the top producers of insulin (it makes about half of the world’s supply currently) and the only producer of semaglutide—more recognizable as its brand names, Ozempic and Wegovy. These brands are used to treat diabetes and obesity, respectively.

Novo Nordisk is also a company with extensive sustainability goals; the company has pledged to reach net-zero carbon dioxide emissions by 2045. One of its early steps toward that goal: it’s the first pharmaceutical company to use...